Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222

To characterize the IgG and IgA responses to different SARS-CoV-2 proteins, we investigated the antibody responses to SARS-CoV-2 following natural infection and following a single dose of AZD1222 (Covishield), in Sri Lankan individuals. The IgG and IgA responses were assessed to S1, S2, RBD, and N p...

Full description

Bibliographic Details
Main Authors: Jayathilaka, D, Jeewandara, C, Gomes, L, Jayadas, TTP, Kamaladasa, A, Somathilake, G, Guruge, D, Pushpakumara, PD, Ranasinghe, T, Aberathna, IS, Danasekara, S, Gunathilaka, B, Kuruppu, H, Wijewickrama, A, Wijayamuni, R, Schimanski, L, Tan, TK, Ogg, GS, Townsend, A, Malavige, GN
Format: Journal article
Language:English
Published: Oxford University Press 2022
_version_ 1826310915218210816
author Jayathilaka, D
Jeewandara, C
Gomes, L
Jayadas, TTP
Kamaladasa, A
Somathilake, G
Guruge, D
Pushpakumara, PD
Ranasinghe, T
Aberathna, IS
Danasekara, S
Gunathilaka, B
Kuruppu, H
Wijewickrama, A
Wijayamuni, R
Schimanski, L
Tan, TK
Ogg, GS
Townsend, A
Malavige, GN
author_facet Jayathilaka, D
Jeewandara, C
Gomes, L
Jayadas, TTP
Kamaladasa, A
Somathilake, G
Guruge, D
Pushpakumara, PD
Ranasinghe, T
Aberathna, IS
Danasekara, S
Gunathilaka, B
Kuruppu, H
Wijewickrama, A
Wijayamuni, R
Schimanski, L
Tan, TK
Ogg, GS
Townsend, A
Malavige, GN
author_sort Jayathilaka, D
collection OXFORD
description To characterize the IgG and IgA responses to different SARS-CoV-2 proteins, we investigated the antibody responses to SARS-CoV-2 following natural infection and following a single dose of AZD1222 (Covishield), in Sri Lankan individuals. The IgG and IgA responses were assessed to S1, S2, RBD, and N proteins in patients at 4 weeks and 12 weeks since the onset of illness or following vaccination. Antibodies to the receptor-binding domain of SARS-CoV-2 wild type (WT), α, β, and λ and ACE2 (Angiotensin Converting Enzyme 2) receptor blocking antibodies were also assessed in these cohorts. For those with mild illness and in vaccines, the IgG responses to S1, S2, RBD, and N protein increased from 4 weeks to 12 weeks, while it remained unchanged in those with moderate/severe illness. In the vaccines, IgG antibodies to the S2 subunit had the highest significant rise (P < 0.0001). Vaccines had several-fold lower IgA antibodies to all the SARS-CoV-2 proteins tested than those with natural infection. At 12 weeks, the haemagglutination test (HAT) titres were significantly lower to the α in vaccines and significantly lower in those with mild illness and in vaccines to β and for λ. No such difference was seen in those with moderate/severe illness. Vaccines had significantly less IgA to SARS-CoV-2, but comparable IgG responses those with natural infection. However, following a single dose vaccines had reduced antibody levels to the VOCs, which further declined with time, suggesting the need to reduce the gap between the two doses, in countries experiencing outbreaks due to VOCs.
first_indexed 2024-03-07T08:00:34Z
format Journal article
id oxford-uuid:7b039117-344b-495b-8066-a4650ba6269f
institution University of Oxford
language English
last_indexed 2024-03-07T08:00:34Z
publishDate 2022
publisher Oxford University Press
record_format dspace
spelling oxford-uuid:7b039117-344b-495b-8066-a4650ba6269f2023-09-26T15:39:54ZKinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7b039117-344b-495b-8066-a4650ba6269fEnglishSymplectic ElementsOxford University Press2022Jayathilaka, DJeewandara, CGomes, LJayadas, TTPKamaladasa, ASomathilake, GGuruge, DPushpakumara, PDRanasinghe, TAberathna, ISDanasekara, SGunathilaka, BKuruppu, HWijewickrama, AWijayamuni, RSchimanski, LTan, TKOgg, GSTownsend, AMalavige, GNTo characterize the IgG and IgA responses to different SARS-CoV-2 proteins, we investigated the antibody responses to SARS-CoV-2 following natural infection and following a single dose of AZD1222 (Covishield), in Sri Lankan individuals. The IgG and IgA responses were assessed to S1, S2, RBD, and N proteins in patients at 4 weeks and 12 weeks since the onset of illness or following vaccination. Antibodies to the receptor-binding domain of SARS-CoV-2 wild type (WT), α, β, and λ and ACE2 (Angiotensin Converting Enzyme 2) receptor blocking antibodies were also assessed in these cohorts. For those with mild illness and in vaccines, the IgG responses to S1, S2, RBD, and N protein increased from 4 weeks to 12 weeks, while it remained unchanged in those with moderate/severe illness. In the vaccines, IgG antibodies to the S2 subunit had the highest significant rise (P < 0.0001). Vaccines had several-fold lower IgA antibodies to all the SARS-CoV-2 proteins tested than those with natural infection. At 12 weeks, the haemagglutination test (HAT) titres were significantly lower to the α in vaccines and significantly lower in those with mild illness and in vaccines to β and for λ. No such difference was seen in those with moderate/severe illness. Vaccines had significantly less IgA to SARS-CoV-2, but comparable IgG responses those with natural infection. However, following a single dose vaccines had reduced antibody levels to the VOCs, which further declined with time, suggesting the need to reduce the gap between the two doses, in countries experiencing outbreaks due to VOCs.
spellingShingle Jayathilaka, D
Jeewandara, C
Gomes, L
Jayadas, TTP
Kamaladasa, A
Somathilake, G
Guruge, D
Pushpakumara, PD
Ranasinghe, T
Aberathna, IS
Danasekara, S
Gunathilaka, B
Kuruppu, H
Wijewickrama, A
Wijayamuni, R
Schimanski, L
Tan, TK
Ogg, GS
Townsend, A
Malavige, GN
Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
title Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
title_full Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
title_fullStr Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
title_full_unstemmed Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
title_short Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
title_sort kinetics of immune responses to sars cov 2 proteins in individuals with varying severity of infection and following a single dose of the azd1222
work_keys_str_mv AT jayathilakad kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT jeewandarac kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT gomesl kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT jayadasttp kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT kamaladasaa kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT somathilakeg kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT guruged kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT pushpakumarapd kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT ranasinghet kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT aberathnais kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT danasekaras kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT gunathilakab kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT kuruppuh kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT wijewickramaa kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT wijayamunir kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT schimanskil kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT tantk kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT ogggs kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT townsenda kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222
AT malavigegn kineticsofimmuneresponsestosarscov2proteinsinindividualswithvaryingseverityofinfectionandfollowingasingledoseoftheazd1222